Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS CROSS REFERENCE TO RELATED APPLICATIONS [001] This application is a non-provisional application which claims the benefit of, and priority to, U.S. Provisional Application No.63/362,302, filed on March 31, 2022, the content of which is hereby incorporated by reference in its entirety.
• FIELD [002] The present disclosure relates to compounds that inhibit the activity of Mucosa Associated Lymphoid tissue lymphoma translocation protein 1 (MALT-1) and compositions containing the compounds.
• MALT-1 Mucosa Associated Lymphoid tissue lymphoma translocation protein 1
• the B and T cells of the adaptive immune system utilize the pleiotropic NF- ⁇ B signaling pathway to transduce extracellular signals from cognate antigen receptors to increase survival and proliferation.
• This signal transduction leads to a rapid nuclear localization of NF- ⁇ B and activation of target genes including proinflammatory cytokines and negative regulators of apoptosis.
• a key downstream signaling hub of the NF- ⁇ B pathway is the CARD11-BCL10- MALT1 (CBM) complex, which plays an essential regulatory role.
• CBM CARD11-BCL10- MALT1
• R 1a is selected from the group consisting of OCH3 and CH3;
• R 1b is selected from the group consisting of CH3, CHF2, and CF3;
• R 2 is selected from the group consisting of H and F;
• R 3 is selected from the group consisting of H and F;
• R 4 is selected from the group consisting of CHF2 and CF3;
• R 5 is C 1 -C 4 alkyl;
• Ring A is a ring selected from the group consisting ;
• R 6 is selected from the group consisting of C 1 -C 4 alkyl and C 1 -C 4 hydroxyalkyl;
• R 7 is selected from the group consisting of H and C1-C4 alkyl; and
• R 8 is selected from the group consisting of CHF2 and CH3.
• Ring A is .
• R 2 is H.
• R 3 is H.
• R 1a is OCH3.
• R 1b is CHF2.
• R 5 is methyl.
• Ring another aspect R 1a is OCH3.
• R 1b is CHF 2 .
• R 6 is C 1 -C 4 alkyl.
• R 5 is C 1 -C 4 alkyl.
• the compound is N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1- methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -N- methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide.
• the present disclosure provides for a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) according to any of the preceding aspects, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
• the present disclosure provides for a method for treating activated B cell-like subtype diffuse large B cell lymphoma (ABC-DLBCL) in a subject comprising administering a therapeutically effective amount of a compound of Formula (I) according to any of the preceding aspects or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
• ABSC-DLBCL activated B cell-like subtype diffuse large B cell lymphoma
• alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
• hydroxyalkyl refers to one or more hydroxy groups (OH) appended to the parent molecular moiety through an alkyl group, as defined herein.
• the hydroxyalkyl group may have one, two, three, or four carbons unless otherwise specified.
• Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl, and the like.
• composition refers to a composition suitable for administration in medical use.
• a pharmaceutically acceptable carrier means a single pharmaceutically acceptable carrier as well as one or more pharmaceutically acceptable carriers, and the like.
• pharmaceutically acceptable salt refers to salts that are within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
• stable refers to compounds that possess stability sufficient to allow manufacture and that maintain the integrity of the compound for a sufficient period of time to be useful for the purpose detailed herein.
• the term "subject,” as used herein, refers to humans.
• the terms “human,” “patient,” and “subject” are used interchangeably herein.
• the phrase “therapeutically effective amount” refers to an amount of a compound, or a pharmaceutically acceptable salt thereof, sufficient to treat one or more of the symptoms of the condition or disorder being treated when administered for treatment in a particular subject or subject population.
• the terms “treat,” “treating,” and “treatment,” as used herein, refer to a method of alleviating or abrogating a disease and/or its attendant symptoms.
• Compounds [032] Compounds of the present disclosure have the general Formula (I) as described herein.
• the present disclosure provides for compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: R 1a is selected from the group consisting of OCH3 and CH3; R 1b is selected from the group consisting of CH3, CHF2, and CF3; R 2 is selected from the group consisting of H and F; R 3 is selected from the group consisting of H and F; R 4 is selected from the group consisting of CHF2 and CF3; R 5 is C 1 -C 4 alkyl; Ring A is a ring selected from the group consisting ; R 6 is selected from the group consisting of C 1 -C 4 alkyl and C 1 -C 4 hydroxyalkyl; R 7 is selected from the group consisting of H and C1-C4 alkyl; and R 8 is selected from the group consisting of CHF2 and CH3.
• R 1a is selected from the group consisting of OCH3 and CH3. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 1a is OCH3. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 1a is CH 3 .
• R 1b is selected from the group consisting of CH3, CHF2, and CF3.
• R 4 is CHF 2 . In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 4 is CF3. [043] In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 1a is OCH3, R 1b is CHF2, R 2 is H, R 3 is H, and R 4 is CF3. [044] In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 5 is C1-C4 alkyl. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 5 is methyl. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 5 is ethyl.
• R 1a is OCH3, R 1b is CHF2, R 2 is H, R 3 is H, R 4 is CF3, R 5 is H, and Ring A is .
• R 7 is selected from the group consisting of H and C1-C4 alkyl. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 7 is H. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 7 is C1-C4 alkyl. In certain embodiments of Formula (I), or a pharmaceutically acceptable salt thereof, R 7 is methyl.
• R 1a is OCH 3
• R 1b is CHF 2
• R 2 is H
• R 3 is H
• R 4 is CF 3
• R 5 is H
• R 8 is selected from the group consisting of CHF2 and CH3.
• R 8 is CHF 2 .
• R 8 is CH3.
• R 1a is OCH 3
• R 1b is CHF 2
• R 2 is H
• R 3 is H
• R 4 is CF 3
• R 5 is H
• Ring
• R 8 is CH3.
• Compounds disclosed herein may contain one or more variable(s) that occur more than one time in any substituent or in the Formulae herein. Definition of a variable at each occurrence is independent of its definition at another occurrence. Further, combinations of substituents are permissible only if such combinations result in stable compounds.
• Compounds of Formula (I) may be used in the form of pharmaceutically acceptable salts.
• Compounds of Formula (I) may contain either a basic or an acidic functionality, or both, and may be converted to a pharmaceutically acceptable salt, when desired, by using a suitable acid or base.
• Methods of Making Exemplary Compounds [059] The compounds of the present disclosure can be better understood in connection with the following synthetic schemes and methods that illustrate a means by which the compounds can be prepared. The compounds of the present disclosure can be prepared by a variety of synthetic procedures. Representative synthetic procedures are shown in, but not limited to, Schemes 1-8.
• Compounds of Formula (1A) wherein R 1A , R 1B , and R 8 are as described herein, may be converted to compounds of Formula (1B) by reacting the former and (R)-3-hydroxy-4,4-dimethyldihydrofuran-2(3H)-one, in the presence of N,N'-dicyclohexylcarbodiimide and 4-dimethylaminopyridine.
• the reaction is typically performed at ambient temperature in a solvent such as, but not limited to, dichloromethane.
• Separation of compounds of Formula (1B) to compounds of Formula (1C) and (1D) can be performed via precipitation techniques as described herein.
• Compounds of Formula (1D) can be subjected to hydrolysis using a base such as lithium hydroxide, followed by the addition of an acid such as hydrochloric acid to provide compounds of Formula (1E).
• the reaction is typically performed in an aqueous environment and may be performed at an elevated temperature, in which the elevated temperature is a temperature greater than ambient temperature, for example greater than 20 °C.
• Compounds of Formula (1F) can be prepared by reacting compounds of Formula (1E) with diphenyl phosphorazidate in tert-butanol in the presence of a base such as triethylamine. The reaction is typically performed at an elevated temperature.
• Compounds of Formula (1G) can be prepared by treating compounds of Formula (1F) with an acid such as 2,2,2-trifluoroacetic acid in a solvent such as dichloromethane. The reaction may be performed at a reduced temperature.
• Compounds of Formula (2D) can be prepared by treating compounds of Formula (2B) with sodium hydride at a reduced temperature followed by addition of a compound of Formula (2C), wherein R 5 and X 1 are as described herein, in a solvent such as, but not limited to, tetrahydrofuran.
• Compounds of Formula (2D) can be treated with hydrochloric acid in a solvent such as 1,4-dioxane, methanol, or a mixture thereof, to provide compounds of Formula (2E).
• Compounds of Formula (1G), wherein R 1A , R 1B , and R 8 are as described herein, can be coupled to compounds of Formula (2G), wherein R 2 , R 3 , R 4 , R 5 and A are as described herein, under Buchwald coupling reaction conditions, which may include the use of a base such as, but not limited to, cesium carbonate and a catalyst such as, but not limited to, XantPhos Pd G3, to provide compounds of Formula (3A).
• the reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, 1,4- dioxane.
• Compounds of Formula (4D) can be prepared by treating compounds of Formula (4C) with [bis(2-methoxyethyl)amino]sulfur trifluoride at low temperature, followed by heat. The reaction is typically performed in a solvent such as, but not limited to, toluene. Treatment of compounds of Formula (4D), at ambient temperature, with a base, such as sodium carbonate, in a solvent, such as methanol, will provide compounds of Formula (4E).
• Compounds of Formula (4F) can be prepared by reacting compounds of Formula (4E) with diphenyl phosphorazidate in tert-butanol in the presence of a base such as triethylamine. The reaction is typically performed at an elevated temperature.
• Compounds of Formula (8A) can be reacted with a compound of Formula (5A) under Buchwald coupling conditions, which include the presence of a base such as, but not limited to, cesium carbonate and a catalyst such as but not limited to XPhos Pd G3, to provide compounds of Formula (8B).
• the reaction is typically performed at an elevated temperature in a solvent such as, but not limited to, dioxane.
• Compounds of Formula (8C) can be prepared by treating compounds of Formula (8B) with an acid such as 2,2,2- trifluoroacetic acid in a solvent such as dichloromethane.
• Compounds of Formula (8D), which are representative of compounds of Formula (I), can be prepared by reacting compounds of Formula (8C) with 2-hydroxyacetic acid in the presence of a coupling agent such as but not limited to 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, and a base such as, but not limited to, N,N-diisopropylethylamine.
• the reaction is typically performed at ambient temperature in a solvent such as, but not limited to, N,N-dimethylformamide.
• compositions When employed as a pharmaceutical, a compound of the present disclosure may be administered in the form of a pharmaceutical composition. Such composition may a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
• Method of Use The compounds of Formula (I) or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, may be administered to a subject suffering from ABC-DLBCL.
• the term “administering” refers to the method of contacting a compound with a subject in need thereof.
• compounds of the present disclosure, or pharmaceutical compositions comprising a compound of the present disclosure may be for use in medicine.
• Example 1D (S)-7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridine-6-carboxylic acid [081]
• a mixture of Example 1B (230 g) and lithium hydroxide hydrate (79 g) in water (1.2 L) was stirred at 80 °C for 1.5 hours.
• the reaction mixture was filtered, and the filtrate was diluted with water (2 L).6 M
• Aqueous HCl was added to adjust the pH to 1.57.
• the mixture was heated to 100 °C over a period of 50 minutes and then stirred at 100 °C for 30 minutes.
• Example 1F (S)-7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-amine [083] To a solution of Example 1E (22.9 g) in anhydrous dichloromethane (201 mL) at 10 °C, was added 2,2,2-trifluoroacetic acid (46.4 mL) over a period of 7 minutes.
• Example 1J (S)-N-(1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N-methyltetrahydro-2H-thiopyran-4- carboxamide 1,1-dioxide [087] To a solution of tetrahydro-2H-thiopyran-4-carboxylic acid 1,1-dioxide (0.83 g) in dichloromethane (20 mL) was added oxalyl chloride (0.41 mL) and N,N-dimethylformamide (0.014 mL). The reaction mixture was stirred at ambient temperature for 1 hour and then concentrated in vacuo.
• Example 1K N-methyl-1,1-dioxo-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1 ⁇ 6 -thiane-4-carboxamide [088] To a degassed mixture of Example 1F (60 mg), Example 1J (127 mg) and cesium carbonate (263 mg) in 1,4-dioxane (6 mL) was added XantPhos Pd G3 ([(4,5- Bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate) (25.5 mg), and the reaction mixture was stirred at 90 °C for 16 hours.
• Example 3C tert-butyl (2-methyl-7-vinylthiazolo[5,4-b]pyridin-6-yl)carbamate [092] To a mixture of Example 3B (73g, 331 mmol, dried by oven), triethylamine (138 mL, 994 mmol, dried with molecular sieves) in toluene (1095 mL, dried with molecular sieves) was added diphenylphosphoryl azide (137 g, 497 mmol).
• tert-butanol (91 mL, 994 mmol, dried with molecular sieves) was added, and the mixture was stirred at 90 °C for 2 hours. After cooling, the mixture was concentrated to small a volume. The residue was poured into water (1000 mL) and extracted with ethyl acetate (3 ⁇ 500 mL). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated to afford a crude product. The crude product was purified by column chromatography (1:3 ethyl acetate / petroleum ether) to afford the title compound.
• Example 3E tert-butyl (7-(2,2-difluoro-1-hydroxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)carbamate [094] To a suspension of Example 3D (50 g, 170 mmol) and triphenylphosphine (71.5 g, 273 mmol) in N,N-dimethyl formamide (350 mL) was added (bromodifluoromethyl)trimethylsilane (42.4 mL, 273 mmol) and the reaction mixture was stirred at 25 °C for 3 hours.1.5 M Potassium hydroxide (352 mL, 528 mmol) was added slowly, and the reaction mixture was stirred for a further 1 hour at 0 °C.
• Example 3F 1-(6-amino-2-methylthiazolo[5,4-b]pyridin-7-yl)-2,2-difluoroethan-1-ol [095]
• a solution of Example 3E (50 g, 145 mmol) in 4 M HCl in 1,4-dioxane (500 mL, 2000 mmol) was stirred for 4 hours at 25 °C and then filtered.
• the filter cake was dissolved in ethyl acetate and basified to about pH 8 with aqueous saturated sodium carbonate solution and extracted with ethyl acetate (4 ⁇ 600 mL).
• the enantiomers were separated by preparative chiral SFC using a CHIRAL ART Cellulose-SB, 5*25 cm, 10 ⁇ m column.
• the conditions used are as follows: Mobile Phase A: CO 2 , Mobile Phase B: isopropyl alcohol (0.5% 2 M ammonia solution in methanol); flow rate: 200 mL/minute; gradient: isocratic 20% B; column temperature: 35 °C; back pressure: 100 bar; wavelength: 220 nm.
• Example 3I N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -N-methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide [097] To a degassed mixture of Example 3G (39 mg), Example 1J (85 mg) and cesium carbonate (147 mg) in 1,4-dioxane (2 mL) was added XantPhos Pd G3 (14.26 mg), and the reaction mixture was stirred at 90 °C for 16 hours.
• the reaction mixture was cooled to ambient temperature, filtered through diatomaceous earth, washing with ethyl acetate (20 mL) and concentrated in vacuo.
• the crude material was purified by chromatography on silica gel (0-100% ethyl acetate/2-methylpentane) to afford the title compound.
• Example 4 N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]ethyl ⁇ -N-methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide
• Example 4A 1-(4-bromophenyl)-2,2-difluoroethan-1-one [098] To a solution of 1-bromo-4-iodobenzene (50 g, 177 mmol) in tetrahydrofuran (500 mL) was added dropwise n-butyllithium (78 mL, 194 mmol).
• Example 4B (S)-1-(4-bromophenyl)-2,2-difluoro-N-methylethanamine [099] To a solution of Example 4A (30 g, 128 mmol), methanamine in ethyl alcohol (39.6 g, 383 mmol) and titanium(IV) isopropoxide (72.6 g, 255 mmol) in dichloromethane (450 mL) was added sodium cyanoborohydride (16.04 g, 255 mmol) portion-wise.
• the reaction mixture was stirred at 40 oC for 16 hours.
• the reaction mixture was quenched with ammonium hydroxide (33% in water) and the solvents were removed in vacuo.
• the residue was purified by flash chromatography (1:1 petroleum ether/dichloromethane).
• the enantiomers were separated on normal phase HPLC using a CHIRALPAK ® OD-H column (20 ⁇ 250 mm, 5 micron), eluting with hexane (0.1% diethylamine)/isopropanol, 20 mL/minute; 10 minutes, to afford the title compound.
• Example 4C N-(4-((S)-2,2-difluoro-1-(methylamino)ethyl)phenyl)-7-((S)-1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-amine [100]
• Example 1F 152 mg, 0.682 mmol
• Example 4B 155 mg, 0.620 mmol
• XPhos Pd G2 48.8 mg, 0.062 mmol
• cesium carbonate (606 mg, 1.859 mmol) were mixed in 1,4- dioxane (8.9 mL). The mixture was sparged with nitrogen for 5 minutes and the vessel was sealed. The reaction was stirred at 90 oC for 16 hours.
• Example 4D N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]ethyl ⁇ -N-methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide
• Tetrahydro-2H-thiopyran-4-carboxylic acid 1,1-dioxide 113 mg, 0.633 mmol
• 2,4- dichloro-6-methoxy-1,3,5-triazine 142 mg, 0.791 mmol
• N-methylmorpholine 87 ⁇ L, 0.791 mmol
• Example 4C A mixture of Example 4C (207 mg, 0.527 mmol) in dichloromethane (2.7 mL) was added, and the mixture was stirred at ambient temperature overnight. The mixture was concentrated and directly purified by reverse phase HPLC (C18 Phenomenex ® LUNA ® , 250 ⁇ 50 mm, 10-90% acetonitrile/0.1% trifluoroacetic acid water solution). The fractions containing the product were concentrated and redissolved in acetonitrile. The sample was desalted by filtering through a 1 g SiliCycle SiliaPrep carbonate cartridge to afford the title compound.
• Example 5 N- ⁇ (1S)-1-[4-( ⁇ 7-[(1S)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -N-methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide
• Example 5A 7-((S)-2,2-difluoro-1-methoxyethyl)-2-methyl-N-(4-((S)-2,2,2-trifluoro-1- (methylamino)ethyl)phenyl)thiazolo[5,4-b]pyridin-6-amine [102]
• Example 3H (1.00 g, 3.86 mmol)
• Example 1I (1.29 g, 4.24 mmol)
• cesium carbonate (3.77 g, 11.6 mmol) in 1,4
• XPhos Pd G4 (methanesulfonato(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'- methylamino-1,1'-biphenyl-2-yl)palladium(ii), 0.33 g, 0.39 mmol) was added, and the reaction mixture was heated 95 °C for 16 hours. The reaction mixture was cooled, filtered through diatomaceous earth, and the diatomaceous earth pad was washed with ethyl acetate. The filtrate was concentrated.
• Example 6 N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2-difluoroethyl ⁇ -N-methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide
• Example 6A N-(4-((S)-2,2-difluoro-1-(methylamino)ethyl)phenyl)-7-((R)-2,2-difluoro-1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-amine [104] The title compound (235 mg, 86%) was prepared using the conditions described in Example 4C substituting Example 3G for Example 1F.
• Example 8 N-methyl-1,1-dioxo-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1R)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1 ⁇ 6 -thiane-4-carboxamide
• Example 8A (R)-7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridine-6-carboxylic acid
• Example 1C (20 g, 54.9 mmol), lithium hydroxide-H 2 O (11.52 g, 274 mmol), tetrahydrofuran (80 mL), and water (40 mL) were stirred at ambient temperature for 24 hours.
• the residue was purified on silica gel (0-40% ethyl acetate/heptanes) to afford the boc-protected aniline.
• the boc-protected aniline was dissolved in a 1:1 mixture of trifluoroacetic acid and CH 2 Cl 2 and stirred at ambient temperature for 1 hour. Upon completion, the solution was concentrated. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium bicarbonate, dried with anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified on silica gel (0-80% ethyl acetate/heptanes) to afford the title compound.
• XPhos Pd G4 (3.27 g, 3.80 mmol) was added, and the reaction mixture was heated at 95 °C for 16 hours. The solution was cooled to 50 °C. Pyrrolidine-1-carbodithioic acid, ammonia salt (2.08 g, 12.7 mmol), and water (5 mL) were added to the reaction mixture. The solution was stirred at ambient temperature for 1 hour. The reaction mixture was filtered through diatomaceous earth, and the filter pad washed with ethyl acetate. The filtrate was concentrated. The residue was purified on silica gel (0-100% ethyl acetate/heptanes).
• Example 11F tert-butyl (2-methyl-7-(2,2,2-trifluoro-1-methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)carbamate
• Potassium carbonate (12.3 g, 89 mmol) and methyl iodide (5.6 mL, 89 mmol) were added to a solution of Example 11E (29.4 g, 81 mmol) in N,N-dimethyl formamide (500 mL).
• the resulting heterogeneous mixture was stirred at ambient temperature for 12 hours, and then diluted with water (1000 mL).
• Example 15B methyl (S)-2-formyl-7-(1-methoxyethyl)thiazolo[5,4-b]pyridine-6-carboxylate [135]
• a mixture of Example 15A (15 g, 56.3 mmol) and selenium dioxide (25.00 g, 225 mmol) in 1,4-dioxane (210 mL) was stirred at 93 °C for 8 hours. After cooling, the reaction mixture was filtrated, concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel eluting with ethyl acetate/petroleum (1:4) to afford the title compound (2.808 g, 9.66 mmol, 17.15%).
• Example 16C tert-butyl (7-(3,3-difluoroprop-1-en-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)carbamate [142] To a suspension of methyltriphenylphosphonium bromide (1270 mg) in tetrahydrofuran (15 mL) at 0 °C was slowly added potassium tert-butoxide (1 M in tetrahydrofuran, 3.23 mL). The reaction was stirred for 40 minutes at this temperature.
• Example 16D tert-butyl (7-(3,3-difluoroprop-1-en-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)carbamate [143] To a solution of Example 16C (130 mg) in tetrahydrofuran (3 mL) was added palladium (5 weight % on carbon, 130 mg). The reaction mixture was stirred under atmosphere of hydrogen (3 bar) at ambient temperature for 3 hours. The reaction mixture was filtered through a glass microfiber pad, washing with methanol (5 mL), and the filtrate was concentrated in vacuo.
• Example 18 1-acetyl-N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4- b]pyridin-6-yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -N-methylpiperidine-4-carboxamide
• Example 18A (S)-1-acetyl-N-(1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N-methylpiperidine-4-carboxamide [147] To a 40 mL vial containing the hydrochloride salt of Example 1I (1.0 g, 3.28 mmol) in dichloromethane (3 mL), pyridine (1.328 mL, 16.42 mmol), and N,N-dimethylpyridin-4-amine (0.401 g, 3.28 mmol) was added 1-acet
• Example 20C N-methyl-N-((S)-2,2,2-trifluoro-1-(4-((7-((S)-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)ethyl)piperidine-4-carboxamide
• dichloromethane 7.5 mL
• trifluoroacetic acid 2.50 mL, 32.4 mmol
• Example 21 N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide
• Example 21A tert-butyl 4-(((S)-1-(4-((7-((R)-2,2-difluoro-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)-2,2,2-trifluoroethyl)(methyl)carbamoyl)piperidine-1-carboxylate [151]
• Example 21A was prepared according to the procedure used for the preparation
• Example 21B N-((S)-1-(4-((7-((R)-2,2-difluoro-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)-2,2,2-trifluoroethyl)-N-methylpiperidine-4-carboxamide, trifluoroacetic acid [152]
• Example 21B was prepared according to the procedure used for the preparation of Example 20C, substituting Example 21A for Example 20B, to provide the title compound. MS (ESI+) m/z 558.4 (M+H) + .
• Example 21C N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide [153]
• Example 21C was prepared according to the procedure used for the preparation of Example 20D, substituting Example 21B for Example 20C, to provide the title compound.
• Example 22 1-(3-hydroxypropanoyl)-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4-carboxamide [154]
• Example 22 was prepared according to the procedure used for the preparation of Example 20D, substituting 30% 3-hydroxypropanoic acid in water for 2-hydroxyacetic acid, to provide the title compound.
• Example 24 1-(2,3-dihydroxypropanoyl)-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4-carboxamide [156]
• Example 24 was prepared according to the procedure used for the preparation of Example 20D, substituting 20% 2,3-dihydroxypropanoic acid in water for 2-hydroxyacetic acid to provide the title compound.
• Example 25 1-[(2R)-2-hydroxypropanoyl]-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]- 2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4-carboxamide [157]
• Example 25 was prepared according to the procedure used for the preparation of Example 20D, substituting (R)-2-hydroxypropanoic acid for 2-hydroxyacetic acid to provide the title compound.
• Example 27 1-[(2R)-2,3-dihydroxypropanoyl]-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1- methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4- carboxamide
• Example 27A (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid [159] To a solution of (R)-methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate (1.00 g, 6.24 mmol) in tetrahydrofuran (10 mL) was added a mixture of lithium hydroxide (0.299 g, 12.5 mmol) in water (10 mL).
• the reaction mixture was stirred at ambient temperature for 2 hours and partitioned with ethyl acetate and water. The organic layer was discarded. The aqueous layer was adjusted to pH 3 by addition of 2 M aqueous HCl and extracted with ethyl acetate three times. The combined organic layers were washed with saturated aqueous sodium chloride, dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford the title compound.
• Example 27B 1-[(2R)-2,3-dihydroxypropanoyl]-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1- methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4- carboxamide
• Example 20C 15 mg, 0.240 mmol
• Example 27A 35.1 mg, 0.240 mmol
• N,N-diisopropylethylamine (0.126 mL, 0.720 mmol) in N,N-dimethyl formamide (2.0 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (100 mg, 0.264 mmol) portion wise.
• the reaction mixture was stirred at ambient temperature for 2 hours, and purified by reverse phase HPLC (250 ⁇ 50 mm C18 Phenomenex ® LUNA, 10-100% acetonitrile/0.1% trifluoroacetic acid water solution) to afford the title compound and the protected intermediate.
• the fractions of protected intermediate were concentrated, dissolved in the mixture of acetic acid (1.0 mL)/water (0.50 mL), stirred at 70 °C for 15 minutes, cooled to ambient temperature and concentrated.
• the residue was purified by reverse phase HPLC (250 ⁇ 50 mm C18 Phenomenex ® LUNA ® , 10-100% acetonitrile/0.1% trifluoroacetic acid water solution).
• Example 4C 126 mg, 0.321 mmol
• dichloromethane 1.6 mL
• the reaction was concentrated and directly purified by flash chromatography (0-70% ethyl acetate/heptanes) to afford the title compound.
• MS (ESI) m/z 604.4 (M+H) + .
• Example 28B N-((S)-2,2-difluoro-1-(4-((7-((S)-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)ethyl)-N-methylpiperidine-4-carboxamide [161] To a mixture of Example 28A (104 mg, 0.172 mmol) in dichloromethane (3.5 mL) was added trifluoroacetic acid (0.67 mL, 8.61 mmol). The mixture was stirred at ambient temperature for 1 hour, and concentrated.
• Example 28C N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]ethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide [162]
• 2-hydroxyacetic acid 5.07 ⁇ L, 0.099 mmol
• N,N-diisopropylethylamine (34.7 ⁇ L, 0.199 mmol) in N,N-dimethylformamide (1.0 mL) was dropwise added a solution of (1-[bis(dimethylamino)methylene]-1H-1,2,3- triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (41.5 mg, 0.109 mmol) in N,
• the mixture was stirred at ambient temperature for 2 hours, and directly purified by reverse phase HPLC (250 ⁇ 50 mm C18 Phenomenex ® LUNA ® , 10-90% acetonitrile/0.1% trifluoroacetic acid water solution).
• the fractions containing the product were concentrated and redissolved in acetonitrile.
• the sample was desalted by filtering through a 1 g SiliCycle SiliaPrep carbonate cartridge to afford the title compound.
• Example 29 1-acetyl-N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 7-[(1S)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4- b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -N-methylpiperidine-4-carboxamide [163] To a solution of Example 28B (45 mg, 0.089 mmol) and triethylamine (31.1 ⁇ L, 0.223 mmol) in N,N-dimethylformamide (0.9 mL) was added acetyl chloride (7.62 ⁇ L, 0.107 mmol) dropwise.
• the mixture was stirred at ambient temperature for 2 hours, and directly purified by reverse phase HPLC (250 ⁇ 50 mm C18 Phenomenex ® LUNA ® , 10-90% acetonitrile/0.1% trifluoroacetic acid water solution).
• the desired fractions were concentrated and redissolved in acetonitrile.
• the sample was desalted by filtering through a 1 g SiliCycle SiliaPrep carbonate cartridge to afford the title compound.
• Example 30 1-[(2S)-2,3-dihydroxypropanoyl]-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1S)-1- methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4- carboxamide [164]
• Example 30 was prepared according to the procedure used for the preparation of Example 20D, substituting (S)-2,3-dihydroxypropanoic acid for 2-hydroxyacetic acid to provide the title compound (26 mg, 18%).
• Example 31B N-((S)-1-(4-((7-((R)-2,2-difluoro-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)-2,2-difluoroethyl)-N-methylpiperidine-4-carboxamide [166] The title compound (70 mg, 83%) was prepared using the conditions described in Example 28B, substituting Example 31A for Example 28A. MS (APCI) m/z 540.4 (M+H) + .
• Example 31C N- ⁇ (1S)-1-[4-( ⁇ 7-[(1R)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2-difluoroethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide [167]
• the title compound (33.4 mg, 43%) was prepared using the conditions described in Example 28C, substituting Example 31B for Example 28B.
• Example 1I (2.50 g, 8.21 mmol), and the combined solution was stirred at ambient temperature for 15 hours. Upon completion as determined by LCMS, the reaction mixture was concentrated. The residue was purified on silica gel (0-100% ethyl acetate/heptanes). The residue was further purified by reverse phase chromatography (C18 HPLC, eluting with 20-100% acetonitrile in water/0.1% trifluoroacetic acid) to isolate the title compound. Clean fractions were combined and concentrated. The aqueous solution was partitioned with ethyl acetate and neutralized with saturated aqueous sodium bicarbonate to free base the desired product.
• Example 32B tert-butyl 4-(((S)-1-(4-((7-((S)-2,2-difluoro-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)-2,2,2-trifluoroethyl)(methyl)carbamoyl)piperidine-1-carboxylate [169]
• Example 3H (0.500 g, 2.24 mmol)
• Example 32A (0.75 g, 1.57 mmol)
• cesium carbonate (1.51 g, 4.63 mmol) in 1,4-dioxane (30 mL) were sparged with N 2 for 2 minutes.
• XPhos Pd G4 (0.20 g, 0.23 mmol) was added, and the reaction mixture was heated at 95 °C for 16 hours. The reaction mixture was cooled, filtered through diatomaceous earth, and the diatomaceous earth pad was washed with ethyl acetate. The filtrate was concentrated. The material was purified on silica gel (0-70% ethyl acetate/heptanes) to afford the title compound.
• Example 32C N-((S)-1-(4-((7-((S)-2,2-difluoro-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)amino)phenyl)-2,2,2-trifluoroethyl)-N-methylpiperidine-4-carboxamide [170]
• Example 32B (0.95 g, 1.45 mmol) was dissolved in a 1:1 mixture of dichloromethane (3 mL) and trifluoroacetic acid (3 mL, 38.9 mmol). The solution was left at ambient temperature for 30 minutes.
• Example 32D N- ⁇ (1S)-1-[4-( ⁇ 7-[(1S)-2,2-difluoro-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6- yl ⁇ amino)phenyl]-2,2,2-trifluoroethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide [171] To a solution of 2-hydroxyacetic acid (0.033 g, 0.43 mmol), Example 32C (0.20 g, 0.36 mmol), N,N-dimethyl formamide (3 mL) and N,N-diisopropylethylamine (0.31 mL, 1.79 mmol) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.15 g, 0.40 mmol) in
• Example 34 1-(hydroxyacetyl)-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1R)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4-carboxamide
• Example 34A tert-butyl 4-(methyl((S)-2,2,2-trifluoro-1-(4-((7-((R)-1-methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)amino)phenyl)ethyl)carbamoyl)piperidine-1-carboxylate [173]
• Example 34A was prepared according to the procedure used for the preparation of Example 32B, substituting Example 8B for Example 3H, to provide the title
• Example 34B N-methyl-N-((S)-2,2,2-trifluoro-1-(4-((7-((R)-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin- 6-yl)amino)phenyl)ethyl)piperidine-4-carboxamide [174]
• Example 34B was prepared according to the procedure used for the preparation of Example 32C, substituting Example 34A for Example 32B to provide the title compound.
• Example 34C 1-(hydroxyacetyl)-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1R)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4-carboxamide [175]
• Example 34C was prepared according to the procedure used for the preparation of Example 32D, substituting Example 34B for Example 32C to provide the title compound.
• Example 35 1-acetyl-N-methyl-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 7-[(1R)-1-methoxyethyl]-2- methyl[1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ piperidine-4-carboxamide [176]
• Example 35 was prepared according to the procedure used for the preparation of Example 33, substituting Example 34B for Example 32C to provide the title compound.
• Example 36 N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 2-methyl-7-[(1R)-2,2,2-trifluoro-1-methoxyethyl][1,3]thiazolo[5,4- b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide
• Example 36A tert-butyl 4-(((S)-2,2-difluoro-1-(4-((2-methyl-7-((R)-2,2,2-trifluoro-1- methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)amino)phenyl)ethyl)(methyl)carbamoyl)piperidine-1- carboxylate [177] The title compound (175.7 mg, 51%) was prepared using the conditions described in Example 28A
• Example 36B N-((S)-2,2-difluoro-1-(4-((2-methyl-7-((R)-2,2,2-trifluoro-1-methoxyethyl)thiazolo[5,4- b]pyridin-6-yl)amino)phenyl)ethyl)-N-methylpiperidine-4-carboxamide [178] The title compound (149.9 mg, 100%) was prepared using the conditions described in Example 28B substituting Example 36A for Example 28A. MS (APCI) m/z 558.4 (M+H) + .
• Example 36C N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 2-methyl-7-[(1R)-2,2,2-trifluoro-1-methoxyethyl][1,3]thiazolo[5,4- b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1-(hydroxyacetyl)-N-methylpiperidine-4-carboxamide [179] The title compound (58.6 mg, 71%) was prepared using the conditions described in Example 28C, substituting Example 36B for Example 28B.
• Example 37 1-acetyl-N- ⁇ (1S)-2,2-difluoro-1-[4-( ⁇ 2-methyl-7-[(1R)-2,2,2-trifluoro-1- methoxyethyl][1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -N-methylpiperidine-4- carboxamide [180]
• the title compound was prepared using the conditions described in Example 29, substituting Example 36B for Example 28B.
• Example 38 N-methyl-1,1-dioxo-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 2-methyl-7-[(2R)-1,1,1-trifluoropropan-2- yl][1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1 ⁇ 6 -thiane-4-carboxamide
• Example 38A [181] To a solution of ethyl 7-chloro-2-methylthiazolo[5,4-b]pyridine-6-carboxylate (50 g, 195 mmol) in 1,4-dioxane (600 mL) and water (500 mL) was added LiOH (4.66 g, 195 mmol).
• Example 38B tert-butyl (7-chloro-2-methylthiazolo[5,4-b]pyridin-6-yl)carbamate [182] To a mixture of Example 38A (30 g, 131 mmol), triethylamine (54.9 mL, 394 mmol) in tert-butanol (600 mL) was added diphenylphosphoryl azide (43.3 g, 157 mmol) and the mixture was stirred at 90 °C for 12 hours. Next, the reaction mixture was concentrated to remove the tert- butanol and the residue obtained was diluted with water (10 mL) and extracted with ethyl acetate (3 ⁇ 20 mL).
• Example 38C tert-butyl (7-iodo-2-methylthiazolo[5,4-b]pyridin-6-yl)carbamate [183]
• Example 38B (12.5 g, 41.7 mmol) was dissolved in acetonitrile (180 mL) and treated with sodium iodide (18.75 g, 125 mmol). The mixture was cooled to 0 °C before the addition of acetyl chloride (3.56 mL, 50.0 mmol). The reaction was stirred for 3 hours at 0 °C. The reaction mixture was poured into a stirred cooled (10 °C) saturated solution of sodium hydrogen carbonate (500 mL).
• Example 38D tert-butyl (2-methyl-7-(3,3,3-trifluoroprop-1-en-2-yl)thiazolo[5,4-b]pyridin-6-yl)carbamate
• Example 38C 2.4 g
• 4,4,6-trimethyl-2-(3,3,3-trifluoroprop- 1-en-2-yl)-1,3,2-dioxaborinane 2.043 g
• cesium carbonate (6.00 g) in 1,2dimethoxyethane (20 mL) and water (2 mL) was added [bis(diphenylphosphino)ferrocene]dichloropalladium(II)- dichloromethane adduct (0.501 g).
• the reaction mixture was stirred under microwave irradiation at 110 °C for 90 minutes.
• the reaction mixture was cooled to ambient temperature and degassed again, and [bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane adduct (0.250 g) was added.
• the reaction mixture was stirred under microwave irradiation at 110 °C for 90 minutes.
• the reaction mixture was cooled to ambient temperature and partitioned between water (30 mL) and ethyl acetate (80 mL).
• the aqueous layer was adjusted to pH 7 by addition of 1 M aqueous HCl and was extracted with ethyl acetate (50 mL).
• Example 38E tert-butyl (2-methyl-7-(1,1,1-trifluoropropan-2-yl)thiazolo[5,4-b]pyridin-6-yl)carbamate [185] To a solution of Example 38D (200 mg) in ethanol (10 mL) was added palladium (5 weight % on carbon, 59.2 mg).
• Example 38F 2-methyl-7-(1,1,1-trifluoropropan-2-yl)thiazolo[5,4-b]pyridin-6-amine [186] To a solution of Example 38E (175 mg) in dichloromethane (5 mL) was added 2,2,2- trifluoroacetic acid (1.119 mL). The reaction mixture was stirred overnight and then concentrated in vacuo.
• Example 38G N-methyl-1,1-dioxo-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 2-methyl-7-[(2R)-1,1,1-trifluoropropan-2- yl][1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1 ⁇ 6 -thiane-4-carboxamide and Example 39 N-methyl-1,1-dioxo-N- ⁇ (1S)-2,2,2-trifluoro-1-[4-( ⁇ 2-methyl-7-[(2S)-1,1,1-trifluoropropan-2- yl][1,3]thiazolo[5,4-b]pyridin-6-yl ⁇ amino)phenyl]ethyl ⁇ -1 ⁇ 6 -thiane-4-carboxamide [187] To a degassed mixture of Example 38F (65 mg), Example 1J (107 mg), and cesium carbonate
• the reaction mixture was cooled to ambient temperature, filtered through diatomaceous earth, washed with dichloromethane (12 mL), and the filtrate was concentrated in vacuo.
• the crude product was purified by chromatography on silica gel (0-25% acetonitrile/dichloromethane) to afford the title compounds as a mixture of diastereomers.
• the mixture of diastereomers was separated by chiral SFC (supercritical fluid chromatography) using a CHIRALPAK ® IG column (10 ⁇ 250 mm, 5 micron), eluting with 40% ethanol (0.1% ammonia) in CO 2 at 40 °C, 15 mL/minute, 120 bar, to afford the title compounds as individual diastereomers.
• Example 38G 1 H NMR (400 MHz, DMSO-d 6 , 90 °C) ⁇ ppm 8.43 (s, 1H), 7.77 (s, 1H), 7.19 (d, 2H), 6.88 – 6.73 (m, 2H), 6.40 (s, 1H), 4.52 (dd, 1H), 3.26 – 3.05 (m, 5H), 2.90 (s, 3H), 2.86 (s, 3H), 2.18 – 2.00 (m, 4H), 1.77 (d, 3H).
• Comparative Example A N- ⁇ (1S)-1-[4-( ⁇ 2-chloro-7-[(1S)-1-methoxyethyl]pyrazolo[1,5-a]pyrimidin-6-yl ⁇ amino)phenyl]- 2,2,2-trifluoroethyl ⁇ -N-methyl-1,1-dioxo-1 ⁇ 6 -thiane-4-carboxamide [188] Comparative Example A was prepared according to the procedure used for the preparation of Example 1K, substituting (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5- a]pyrimidin-6-amine for Example 1J to provide the title compound.
• Comparative Example B (S)-1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea [189] Comparative Example B was prepared as described in WO2018020474, Compound 142.
• MALT-1 Biochemical Assay A Quenched Fluorescence Resonance Energy Transfer (Quench-FRET) enzyme assay was used to test the ability of exemplary MALT-1 inhibitors Example 1 to Example 39 to inhibit the cleavage of a MALT1 specific quenched fluorescent substrate of sequence [TAMRA- PEG2-Leu-Val-Ser-Arg-Gly-Ala-Ala-Ser-PEG2-K(QSY7) by human MALT-1 protein; where TAMRA is 6-carboxytetramethylrhodamine, PEG2 is 2-(2-(2-aminoethoxy)ethoxyamide linker, QSY7 is a non-fluorescent quenching dye (Thermo-Fisher catalog #Q10193).
• the assay was performed by pre-dispensing compounds into 384 well ProxiplatesTM (PE 6008289).
• Human MALT-1 (6 nM) was prepared using the assay buffer (25 mM HEPES pH 7.5, 1 mM ethylenediaminetetraacetic acid, 0.8 M sodium citrate, 0.005% Bovine serum albumin (BSA), 2 mM dithiothreitol (DTT)) and added to the compound plates. The plates were incubated 40 minutes at room temperature. The reaction was carried out by adding the substrate (2 ⁇ M) to the plates and incubating for 60 minutes at room temperature. A fluorescence readout was then measured using a PE EnVision ® reader (Ex.535/Em.590). The results of the enzyme assay are provided subsequently in Table 2 and demonstrate the ability of the compounds of the present disclosure to inhibit MALT-1 protease activity.
• EC50 is defined as the half maximal effective concentration of compound to inhibit MALT-1 protease activity. Table 2.
• MALT-1 Cell IL-6 AlphaLISA Assay [191] The following MALT-1 Cell Interleukin-6 (IL-6) AlphaLISA assay was conducted using a Perkin Elmer ® IL-6 AlphaLISA ® detection kit (PE AL223).
• the IL-6 detection assay is a homogeneous immunoassay that detects human IL-6 present in the cell culture medium in the MALT-1 dependent human ABC-DLBCL cell line, OCI-LY3. Compounds were pre-dispensed into Black 384w microtiter plates (Greiner, 781090) from 30 ⁇ M to 1.5 nM. Viable OCI-LY3 cells were then seeded on top of compounds at a seeding density of 50,000 cells/mL.
• Cardiovascular Assay The following cardiovascular assay was conducted using male Sprague-Dawley rats that were anesthetized with Inactin (thiobutabarbital), instrumented (catheterized both femoral artery and vein; catheterize left ventricular) and allowed to stabilize. Following a 30-minute baseline period, each compound was infused at low, medium, and high doses/30 minutes. Plasma samples were taken at the end of each dose infusion. If, at any point, the mean arterial pressure (MAP) of an animal decreased below 70 mmHg, the infusion was immediately stopped, a final blood sample was taken, and hemodynamic data for that animal was removed from the group average for all subsequent time points. A 15% change from vehicle for MAP or heart rate (HR), respectively, is considered biologically relevant. A 20% change from vehicle for dP/dt@50 is considered biologically relevant. Results are shown in Table 4. Table 4.
• CYP3A4 Induction Assay [193] CYP induction by compounds of the Examples was evaluated in vitro by determining the expression levels of CYP 3A4 mRNA using the qPCR (quantitative polymerase chain reaction) assay. On day one, cryopreserved human hepatocytes were thawed in prewarmed (37 °C) thawing medium (cryopreserved hepatocyte recovery medium, Gibco TM CM 7000; Thermo Fisher Scientific), centrifuged (1000 g for 10 minutes) and resuspended in plating medium (Gibco TM CM3000 – Williams Medium E supplemented with hepatocytes plating supplement pak- serum containing; Thermo Fisher Scientific).
• RNA isolation was performed. All surfaces were cleaned using RNase RNAy. Total RNA was isolated using MagMAX Express 96 RNA Isolation System (Life Technologies, AM1830).
• hepatocytes were washed once with 1X PBS (phosphate buffered saline).145 ⁇ L of RNA Lysis Buffer was added to each well and each well was mixed by pipetting several times. Lysate was then transferred to a well of a 96 well Binding Plate. Samples were then mixed with 20 ⁇ L magnetic beads coming from the kit. RNA bound to beads was then captured by the magnetic tip manifold and beads were washed with the wash solution. Samples were treated with TURBO TM DNase. After TURBO TM DNase treatment, RNA was rebound to beads and washed with the provided wash buffer an additional two times. Beads are then dried, and RNA was eluted with 50 ⁇ L elution buffer.
• 1X PBS phosphate buffered saline
• RT reverse transcription
• RT master mix was prepared by mixing 2.5 ⁇ L 10X RT buffer, 5.5 ⁇ L 25 mM MgCl 2, 5 ⁇ L deoxyNTP mixture, 1.25 ⁇ L 50 mM random hexamers, 0.5 ⁇ L 2X RNAse inhibitor, 0.625 ⁇ L multiscript RTase (50U/ ⁇ L) and 0.625 ⁇ L water.
• qPCR thermal cycling conditions segment 1: 50 °C held for 10 minutes; segment 2: 95 °C held for 3 minutes; followed by 40 cycles of segment 3: 95 °C for 15 seconds and segment 4: 60 °C for 1 minute.
• qPCR comparative quantitative real-time polymerase chain reaction

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=86185307

Family Applications (1)

Country Status (13)

Cited By (2)

Citations (2)

Family Cites Families (73)

• 2023
  • 2023-02-17 TW TW112105833A patent/TW202345806A/zh unknown
  • 2023-03-29 WO PCT/US2023/065111 patent/WO2023192913A1/en not_active Ceased
  • 2023-03-29 KR KR1020247035987A patent/KR20240168420A/ko active Pending
  • 2023-03-29 AR ARP230100771A patent/AR128917A1/es unknown
  • 2023-03-29 JP JP2023052720A patent/JP7723030B2/ja active Active
  • 2023-03-29 EP EP26162991.9A patent/EP4729059A2/en active Pending
  • 2023-03-29 CA CA3246085A patent/CA3246085A1/en active Pending
  • 2023-03-29 CN CN202380037777.2A patent/CN119855821A/zh active Pending
  • 2023-03-29 IL IL316288A patent/IL316288A/en unknown
  • 2023-03-29 EP EP23719616.7A patent/EP4499650A1/en active Pending
  • 2023-03-29 AU AU2023243460A patent/AU2023243460A1/en active Pending
  • 2023-03-30 US US18/192,810 patent/US11993613B2/en active Active
• 2024
  • 2024-04-18 US US18/638,727 patent/US20250084099A1/en active Pending
  • 2024-09-27 MX MX2024012018A patent/MX2024012018A/es unknown
  • 2024-10-21 AR ARP240102836A patent/AR134155A2/es unknown
  • 2024-10-25 CO CONC2024/0014618A patent/CO2024014618A2/es unknown
• 2025
  • 2025-07-31 JP JP2025128083A patent/JP2025156455A/ja active Pending

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events